Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04596475 · ClinicalTrials.gov registry record · Phase 1
Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04596475 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 12 participants.
The verdict
NCT04596475, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This trial will be done in participants who undergo transplantation of heart, kidney or lung at University of California, San Diego (UCSD) and receive a hepatitis C infected donor organ. In this trial, the plan is to start hepatitis C treatment just before transplant surgery and treat for a short one-week course to see if hepatitis C infection can be prevented in the transplant recipient. The plan is to perform this trial in 10 participants and if successful, the next step is to try to make it standard of care as prevention of infection is better than treating hepatitis C after discharge from transplant surgery (which is usually a 12 week standard treatment).
Interventions
- DRUG glecaprevir/pibrentasvir (GLE/PIB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-05-28 |
| Est. Completion | 2022-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04596475
The ClinicalTrials.gov registry entry for NCT04596475 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which glecaprevir/pibrentasvir (GLE/PIB) is the first listed.
NCT04596475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04596475 about?
NCT04596475 is a clinical study titled "Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor". This trial will be done in participants who undergo transplantation of heart, kidney or lung at University of California, San Diego (UCSD) and receive a hepatitis C infected donor organ. In this trial, the plan is to start hepatitis C treatment just before transplant surgery and treat for a short on...
What is the current status of trial NCT04596475?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-05-28. Estimated completion is 2022-04-21.
What interventions are being tested in trial NCT04596475?
The interventions under investigation include: glecaprevir/pibrentasvir (GLE/PIB) (DRUG).
Who is sponsoring clinical trial NCT04596475?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.